Atlas Trials

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

Clinical trial NCT06808984 · RECRUITING

Trial details

NCT number
NCT06808984
Sponsor
Celgene
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
AgitationAlzheimer Disease
Start date
2025-06-09
Primary completion
2027-11-26
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.